Flavia Borellini
Fortune : 5 M $ au 31/07/2026
Fortune : 5 M $ au 31/07/2026
Dr. Flavia Borellini is an Independent Director at Pliant Therapeutics, Inc., an Independent Director at Revolution Medicines, Inc. and an Independent Director at Cantargia AB. She is on the Board of Directors at Pliant Therapeutics, Inc., Revolution Medicines, Inc., Cantargia AB and Kartos Therapeutics, Inc. Dr. Borellini was previously employed as an Independent Director by Viracta Therapeutics, Inc., a Global Head-Hematology Franchise by AstraZeneca PLC, a Chief Executive Officer by Acerta Pharma BV, a Vice President-Program Leadership by Onyx Pharmaceuticals, Inc., and a Member by Roche Group.
She received her doctorate degree from Università degli Studi di Modena e Reggio Emilia.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/06/2026 | 26 215 ( 0,01 % ) | 5 M $ | 31/07/2026 | |
| 09/07/2026 | 0 ( -.--% ) | - $ | 31/07/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| REVOLUTION MEDICINES, INC. | Directeur/Membre du Conseil | 22/06/2021 |
| CANTARGIA AB | Directeur/Membre du Conseil | 01/10/2020 |
| PLIANT THERAPEUTICS, INC. | Directeur/Membre du Conseil | 09/07/2026 |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company that develops novel and targeted therapeutics | Directeur/Membre du Conseil | 01/02/2018 |
| Sociétés | Poste | Fin |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 05/02/2025 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/01/2020 |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Develops drugs for oncology and autoimmune diseases | Directeur Général | 01/02/2019 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Corporate Officer/Principal | 01/10/2013 |
Roche Group
Roche Group Real Estate DevelopmentFinance Manages real estate properties | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 10 |
|---|---|
AstraZeneca PLC
AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
Roche Group
Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
Università degli Studi di Modena e Reggio Emilia
Università degli Studi di Modena e Reggio Emilia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cantargia AB
Cantargia AB Pharmaceuticals: MajorHealth Technology Creates and develops antibody therapeutics for the treatment of leukemia | Health Technology |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Develops drugs for oncology and autoimmune diseases | Health Technology |
Revolution Medicines, Inc.
Revolution Medicines, Inc. Pharmaceuticals: OtherHealth Technology Develops new therapies derived from natural products | Health Technology |
Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. BiotechnologyHealth Technology Operates as biopharmaceutical company focuses on discovering and developing novel therapies for the treatment of fibrosis | Health Technology |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company that develops novel and targeted therapeutics | Health Technology |
Viracta Therapeutics, Inc.
Viracta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for virus-associated cancers | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national